{"filings":[{"id":2219037,"accession_number":"0001522767-26-000164","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2026-08-12T21:07:15+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed Q2 2026 revenue up 6% to $41.9M; net loss widens to $3.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $41.9M in Q2 2026, up 6% from $39.5M in Q2 2025; H1 revenue $81.4M vs $77.4M.","GAAP net loss widened to $3.6M in Q2 vs $1.4M a year ago; non-GAAP net loss $2.4M vs $0.3M profit.","Non-GAAP adjusted EBITDA fell to $3.9M (9% margin) from $4.8M (12% margin) in Q2 2025.","GAAP gross margin 39% vs 40%; non-GAAP gross margin 40% vs 42%, down YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":918596,"accession_number":"0001522767-26-000107","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2026-06-08T20:18:13+00:00","items":["5.07"],"status":"ready","headline":"MariMed stockholders re-elect four directors and approve auditors at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Re-elected directors Levine, Gildea, Allen, and Selhub; each received over 110M votes for.","Advisory approval of M&K CPAs PLLC as FY2026 auditors: 229.3M for, 15.6M against, 0.6M abstain.","Broker non-votes of 119.8M shares on director elections due to discretionary voting rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":70522,"accession_number":"0001522767-26-000070","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2026-05-13T21:13:09+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed Q1 revenue $39.5M (+4.2% YoY); net loss narrows to $3.8M; adj. EBITDA $3.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $39.5M, up 4.2% YoY from $37.9M.","GAAP net loss $3.8M, improved from $5.5M loss in prior year.","Non-GAAP net loss $3.2M, improved from $3.9M.","Adjusted EBITDA $3.6M (9% margin) vs $2.5M (7% margin) YoY.","Gross margin slightly declined: GAAP 39% (vs 40%), Non-GAAP 40% (vs 41%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104989,"accession_number":"0001522767-26-000027","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed reports FY2025 revenue of $159.8M, net loss widens to $14.5M, adjusted EBITDA down to $16.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 revenue $159.8M, up from $157.7M in FY2024; Q4 revenue $41.7M vs $38.9M.","GAAP net loss $14.5M in FY2025 vs $12.4M; Non-GAAP adjusted EBITDA $16.9M, down from $19.3M.","Wholesale revenue increased 11%; distribution reached 85% of dispensaries in core markets.","Betty's Eddies ranked #1 edible in MA, MD, DE, IL; restructured Series B debt, extending maturity 4.6 years.","CEO cites growth drivers for 2026: Delaware adult-use, Maine brand licensing, new Columbus OH dispensary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104988,"accession_number":"0001522767-26-000011","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["1.01","2.03","3.02","5.03","9.01"],"status":"ready","headline":"MariMed restructures $14.2M Series B obligation with $8M notes and 26.9M preferred shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Old Series B preferred (4,908,333 shares) cancelled, avoiding ~$14.2M cash payout upon mandatory conversion on Feb 28, 2026.","Issued $2M note due March 2028 at 8% and $6M note due March 2031 at 10% (reduces to 8% if $2M note repaid within 6 months).","Issued 26.9M shares of new Series B Convertible Preferred Stock with $0.25/sh liquidation preference ($6.725M aggregate).","New preferred ranks senior to common on dividends/liquidation; conversion options with VWAP-based mechanics.","Restructuring extinguished all prior obligations to Navy Capital Green; no stockholder approval was required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121232,"accession_number":"0001522767-25-000222","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed Q3 revenue $40.8M, adjusted EBITDA $5.1M; expands brands to 3 new states","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue flat at $40.8M (Q3 2024: $40.6M); GAAP net loss widened to $2.9M from $1.0M.","Adjusted EBITDA rose to $5.1M from $4.7M; margin improved to 13% from 12% YoY.","Sequential growth in wholesale and retail; new brand distribution agreements in Maine, Pennsylvania, and New York.","Delaware adult-use sales launched; Metropolis, IL location impacted by new competition.","Nine-month revenue $118.2M vs $118.8M; GAAP net loss $9.8M vs $4.2M."],"consensus_eps_estimate":-0.0102,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":118176000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137881,"accession_number":"0001522767-25-000167","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed Q2 revenue $39.6M, adjusted EBITDA $4.9M; net loss narrows YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $39.6M for Q2 2025, down 2% YoY from $40.4M; GAAP net loss improved to $1.3M from $1.6M.","Non-GAAP adjusted EBITDA of $4.9M (12% margin), up from $4.4M (11% margin) in Q2 2024; company was cash flow positive.","CEO cites 'Expand the Brand' strategy; growth in Massachusetts, full-quarter Delaware contributions, and entry into Pennsylvania.","Six-month net loss widened to $6.7M from $2.9M, while non-GAAP net loss also widened; adjusted EBITDA margin fell to 10%.","Company anticipates catalysts in H2: adult-use Delaware, new Maine license, Pennsylvania entry, and M&A optionality."],"consensus_eps_estimate":-0.0102,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":77566000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155265,"accession_number":"0001522767-25-000130","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MariMed shareholders re-elect four directors and ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Four directors re-elected: Jon R. Levine, Edward Gildea, David Allen, Eva Selhub, each with >107M votes for.","Advisory approval of M&K CPAs PLLC as auditor for FY2025: 204M for, 10.5M against, 4.6M abstain.","Broker non-votes of ~103.5M shares on director election reflect shares not voted on management proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155264,"accession_number":"0001522767-25-000048","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed Q1 revenue flat at $38.0M; net loss widens to $5.4M from $1.3M YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $38.0M flat vs $37.9M a year ago; GAAP gross margin fell to 40% from 43%.","GAAP net loss of $5.4M widened from $1.3M loss; Non-GAAP net loss $3.8M vs $0.6M.","Non-GAAP Adjusted EBITDA dropped to $2.6M (7% margin) from $4.7M (12% margin).","Wholesale sales rose to 44% of revenue; 70 new storefronts added; Betty's Eddies top edible in MA, MD, DE.","Management cites soft retail quarter, ramp-up costs in IL and MO; eyes M&A, licensing, hemp entry."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":37955000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173776,"accession_number":"0001522767-25-000010","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed reports record FY2024 revenue $158M; Q4 margins compress, adjusted EBITDA up in Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $39.0M (vs $38.9M); full-year revenue $158.0M (+6.3% YoY).","GAAP gross margin fell to 33% in Q4 from 45% YoY; full-year margin 40% vs 44%.","Full-year GAAP net loss improved to $12.1M from $16.0M; adjusted EBITDA $19.6M vs $24.7M.","Wholesale revenue up 29% annually; Betty's Eddies top-selling edible in MA and MD.","CEO cites 10 revenue-generating assets added over past two years for 2025 growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190761,"accession_number":"0001522767-24-000088","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed Q3 revenue up 5% to $40.6M; net loss narrows to $1.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $40.6M, +5% YoY; adjusted EBITDA $4.7M vs $6.1M in Q3 2023.","GAAP net loss $1.0M improved from $4.3M loss; non-GAAP net income $0.5M.","Wholesale revenue grew at least 20% YoY; retail transactions increased YoY.","Nine-month revenue $119.0M, up 8.5% YoY; adjusted EBITDA $13.7M vs $19.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":118962000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207237,"accession_number":"0001522767-24-000069","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"MariMed appoints Mario Pinho as CFO; 300,000 RSU inducement award","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective Aug 9, 2024, Mario Pinho named CFO, replacing interim CFO Jon Levine.","Pinho receives 300,000 RSUs inducement award, $265K base salary, and 30% performance bonus.","Levine remains President and CEO of MariMed.","Pinho, 57, CPA, previously CFO at Rakuten USA (2016-2024) and senior roles at American Express and KPMG."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207236,"accession_number":"0001522767-24-000063","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed Q2 2024 revenue $40.4M, GAAP net loss $1.6M, adjusted EBITDA $4.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $40.4M, up 10.7% YoY from $36.5M; gross margin 42% (GAAP), 43% (non-GAAP).","GAAP net loss $1.6M vs loss $0.9M in Q2 2023; non-GAAP net loss $0.2M vs income $0.6M.","Non-GAAP adjusted EBITDA $4.4M (11% margin), down from $6.3M (17% margin) a year ago.","Retail transactions increased 24% YoY; wholesale segment led overall growth.","Management reaffirms 2024 financial targets; expects margin expansion and improved cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":78371000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224607,"accession_number":"0001522767-24-000045","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MariMed stockholders re-elect five directors and approve auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Re-elected Jon R. Levine, Edward Gildea, David Allen, Eva Selhub, and Kathleen Tucker as directors.","Advisory approval of M&K CPAs PLLC as independent auditors for fiscal 2024 with 205.2M votes for.","Meeting held June 6, 2024; all proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224606,"accession_number":"0001522767-24-000040","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed Q1 2024 revenue up 10% to $37.9M; net loss widens to $1.3M, adjusted EBITDA down","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $37.9M (+10% YoY); GAAP gross margin 43% vs 45% in prior year.","GAAP net loss $1.3M (vs $0.7M loss); non-GAAP net loss $0.6M (vs $0.3M income).","Adjusted EBITDA $4.7M vs $7.1M; margin 12% vs 21%; CEO cites wholesale growth.","17th consecutive quarter of positive adjusted EBITDA; management reaffirms strategic plan."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":37933000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243902,"accession_number":"0001522767-24-000005","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed Q4 revenue $38.9M (+8.6% YoY); GAAP net loss $10.1M; announces MD dispensary acquisition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $38.9M, up 8.6% from $35.8M in Q4 2022; full year revenue $148.6M, up 10.9% from $134.0M.","GAAP net loss of $10.1M in Q4 vs net income of $4.8M in prior year; full year net loss $16.0M vs net income $13.6M.","Non-GAAP adjusted EBITDA $5.2M in Q4 (14% margin) vs $4.5M in Q4 2022; full year $24.7M (17% margin) vs $32.4M (24% margin).","Company announces pending acquisition of a dispensary in Upper Marlboro, Maryland, expanding its footprint in the state.","CEO cites sixth consecutive year of double-digit revenue growth and positive adjusted EBITDA; wholesale operations in Illinois contributing to 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261310,"accession_number":"0001522767-23-000129","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2023-11-20T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"MariMed closes $58.7M debt refinancing at 8.43% fixed rate; expects $4.7M savings in first year","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["10-year loan from Needham Bank with interest-only payments for first 12 months, then 20-year amortization.","Proceeds used to pay off $46.8M in existing debt (Chicago Atlantic, Bank of New England, Ermont seller note).","Remaining funds held in escrow for Hagerstown, MD cultivation facility expansion.","Loan secured solely by MD and MA assets; IL, OH, DE assets and brands (Betty's Eddies, Nature's Heritage) now unencumbered.","No warrants or equity component; estimated $3.5M annual savings in years 2-5."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261309,"accession_number":"0001522767-23-000119","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed Q3 revenue $38.8M (+14% YoY), GAAP net loss of $4.3M vs profit a year ago","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $38.8M for Q3 2023, up 14% from $33.9M in Q3 2022.","GAAP net loss of $4.3M, compared to net income of $2.7M in the prior-year quarter.","Non-GAAP adjusted EBITDA of $6.1M (16% margin) vs $8.6M (25% margin) a year ago.","Reported 15th consecutive quarter of positive adjusted EBITDA.","Maryland adult-use sales launched July 1; wholesale business set quarterly records."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":109699000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261308,"accession_number":"0001522767-23-000115","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CFO Susan M. Villare resigns; CEO Jon R. Levine appointed interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Susan M. Villare resigned as CFO of MariMed Inc., effective October 31, 2023.","CEO Jon R. Levine appointed as interim CFO while a permanent replacement is sought.","A search process for a new CFO has been initiated by the Board of Directors.","Resignation letter filed as Exhibit 99.1 to the Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278552,"accession_number":"0001522767-23-000100","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed Q2 revenue $36.5M (+11% YoY); GAAP net loss $0.9M vs $1.9M profit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $36.5M, up 11% from $33.0M year-over-year; wholesale set monthly and quarterly records.","GAAP net loss $0.9M vs income $1.9M in Q2 2022; non-GAAP net income $0.6M vs $5.5M.","Adjusted EBITDA $6.3M (17% margin) down from $8.9M (27% margin) last year; 14th straight positive quarter.","Non-GAAP gross margin 46% flat YoY; balance sheet remains one of strongest in industry.","Adult-use sales in Maryland commenced July 1, 2023, driving expected acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":70899000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296755,"accession_number":"0001522767-23-000095","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2023-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MariMed stockholders re-elect directors and approve auditors at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Five directors re-elected: Levine, Allen, Gildea, Selhub, Tucker; each received >111M votes for, 1-2.5M withheld.","Advisory approval of auditors (M&K CPAs PLLC) passed with 205.6M for, 1.8M against, 0.3M abstain.","Broker non-votes of 93.3M shares present on director elections, not counted for auditor vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296754,"accession_number":"0001522767-23-000075","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed Q1 revenue up 10% YoY to $34.4M but GAAP net loss of $0.7M vs prior-year profit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $34.4M vs $31.3M YoY (+10%); GAAP gross margin fell to 45% from 54%.","GAAP net loss $(0.7)M vs net income $4.2M a year ago; non-GAAP net income $0.3M.","Adjusted EBITDA $7.1M (21% margin) down from $10.4M (33% margin) in Q1 2022.","CEO notes 13th consecutive quarter of positive adjusted EBITDA; expects 4th straight year of positive operating cash flow.","Non-GAAP adjusted EBITDA margin declined to 21% from 33% on higher costs and product mix."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":34380000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296753,"accession_number":"0001522767-23-000045","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2023-04-17T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"MariMed appoints Kathleen Tucker to Board, filling vacancy from former CEO's passing","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kathleen Tucker, age 63, joined Board effective April 17, 2023, as the fifth director and fourth independent director.","She fills the vacancy left by Robert Fireman, former Chairman and CEO, who passed in December 2022.","Tucker has 25+ years of executive experience at VISA, FTD, and cannabis companies; currently CEO of Presence Enterprises.","Board committee assignments to be determined at the meeting following the next annual stockholder meeting.","CEO Jon Levine highlighted Tucker's consumer marketing and e-commerce expertise to support MariMed's growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317146,"accession_number":"0001522767-23-000023","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2023-03-06T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"MariMed appoints Edward Gildea as Chairman and Jon R. Levine as CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Edward Gildea appointed Chairman of the Board, effective February 28, 2023.","Jon R. Levine appointed Chief Executive Officer, effective February 28, 2023.","Board amended Bylaws to revise powers and duties of Chairman, CEO, and President.","Amendment to Bylaws filed as Exhibit 3.2(A) with this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317145,"accession_number":"0001522767-23-000009","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2023-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed Q4 revenue up 15.5% YoY to $35.8M; net income turns positive but EBITDA margin shrinks","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $35.8M (+15.5% YoY); full-year revenue $134.0M (+10.3% YoY).","GAAP net income Q4 $4.8M vs loss of $6.4M in prior year; full-year net income $13.6M (+79% YoY).","Non-GAAP adjusted EBITDA Q4 $4.5M (down 46% YoY); full-year $32.4M (down 24% YoY).","GAAP gross margin Q4 44% vs 50% prior year; full year 48% vs 55%.","CEO: positive cash flow from ops for third consecutive year; expects accelerated growth in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":134010000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317144,"accession_number":"0001522767-23-000004","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2023-01-24T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"MariMed closes $35M credit facility with Chicago Atlantic to fund expansion and acquisitions","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $30M at close of $35M secured credit facility; can draw additional $5M over six months.","Funds will complete IL cultivation/processing facility, MO processing kitchen, expand MA and MD facilities, and repay Kind Therapeutics seller notes.","Interest rate floating at prime plus 5.75%; warrants issued: 19,148,936 shares at $0.47 per share (30% coverage at 20% premium).","Debt/EBITDA ratio of 1.5X and blended interest rate of 10.5% among lowest in cannabis industry.","Maturity of three years with potential extension to five years; no prepayment penalty after 20 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335398,"accession_number":"0001522767-22-000023","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2022-12-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MariMed appoints Jon Levine as Interim CEO after passing of Robert Fireman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jon Levine, previously President, named Interim CEO effective immediately; retains President role.","Board will search for permanent CEO; external and internal candidates considered; no timeline given.","Announcement follows the passing of former CEO Robert Fireman.","MariMed is a multi-state cannabis operator with brands including Betty's Eddies and Nature's Heritage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335397,"accession_number":"0001522767-22-000020","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2022-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MariMed CEO and Chairman Robert Fireman dies unexpectedly on Dec 11","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Fireman, CEO since 2017 and co-founder, passed away unexpectedly on Dec 11, 2022.","Board will determine succession; President Jon Levine expresses commitment to continue Fireman's vision.","Fireman led MariMed's expansion into multiple state-licensed cannabis cultivation, production, and retail facilities.","No financial impact or operational changes disclosed beyond leadership transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335396,"accession_number":"0001522767-22-000012","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed Q3 revenue $33.9M (+2% YoY); adjusted EBITDA falls 32% to $8.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $33.9M vs $33.2M in Q3 2021, a 2% YoY increase.","GAAP net income $2.7M, up from $2.1M YoY.","Non-GAAP adjusted EBITDA $8.6M, down from $12.6M YoY; margin 25% vs 38%.","Gross margin declined to 48% from 55% YoY.","CEO cites industry headwinds but highlights strength in retail and wholesale."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":98180000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335395,"accession_number":"0001493152-22-030007","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2022-10-31T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MariMed shareholders re-elect five directors, approve auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees received >99% of votes cast (excluding broker non-votes).","Robert Fireman: 138,918,236 for, 1,753,185 withheld; Jon R. Levine: 138,002,182 for, 2,669,239 withheld.","David Allen, Edward Gildea, and Eva Selhub also re-elected with similar margins.","Advisory approval of M&K CPAs PLLC as auditors passed: 227,091,546 for, 537,750 against.","Broker non-votes totaled 88,203,033 on each director election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352823,"accession_number":"0001493152-22-025249","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2022-09-07T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"MariMed promotes Jon Levine to President, effective Sept 7, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jon Levine promoted from Chief Administrative Officer to President; co-founded MariMed with CEO Bob Fireman.","Robert Fireman remains CEO and Chairman; Levine's role includes day-to-day oversight and capital markets support.","Levine's employment agreement amended to reflect new title and responsibilities.","Levine previously served as CFO and CAO, overseeing sales, marketing, operations, and financial reporting.","CEO states promotion allows him to focus on strategic growth and capitalize on cannabis industry consolidation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352822,"accession_number":"0001493152-22-021653","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MariMed Q2 revenue $33.0M (+1% YoY); GAAP net income falls 75% to $1.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $33.0M vs $32.6M year ago; gross margin dropped to 45% from 60%.","GAAP net income $1.9M vs $7.6M; Non-GAAP Adjusted EBITDA $8.9M vs $13.9M.","Working capital declined to $8.9M from $13.9M; no guidance provided.","CEO cited increased dispensary traffic despite industry headwinds and 40-year high inflation."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":64268000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370426,"accession_number":"0001493152-22-014273","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2022-05-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"MariMed appoints Susan Villare as CFO; Jon Levine promoted to CAO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Susan Villare named CFO effective May 11, 2022; succeeds Jon Levine.","Villare receives 350k restricted shares + options for 400k shares at $0.64.","Annual base salary of $285,000; eligible for 35% performance bonus.","Jon Levine promoted to Chief Administrative Officer; employment agreement amended.","Villare previously SVP of FP&A at Ribbon Communications; CPA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370425,"accession_number":"0001493152-22-013779","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2022-05-16T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MariMed Q1 revenue up 27% to $31.3M; adj EBITDA $10.4M, guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $31.3M (up 27% YoY); gross margin 54.3% vs 53.5%; net income $4.2M (flat YoY).","Non-GAAP adjusted EBITDA $10.4M (+29% YoY); cash from operations $8.5M; working capital $20.1M.","Closed Maryland and Illinois acquisitions post-quarter; plans CSE listing to boost liquidity.","FY 2022 guidance held: revenue $145-150M, gross margin 54-55%, adj EBITDA $47-52M, capex ~$25M.","Retail dispensary revenue grew 41% YoY; wholesale up 6%; launched THC-infused drink mixes in MA."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":31282000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370424,"accession_number":"0001493152-22-009916","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2022-04-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MariMed gets Maryland approval to acquire Kind Therapeutics; over 139K patients in state program","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["MMCC approved transfer of 100% ownership of Kind Therapeutics to MariMed on April 13, 2022.","Kind operates a cultivation/production facility in Hagerstown, MD and is developing a dispensary in Anne Arundel County.","Maryland's medical cannabis program has over 139,000 patients and generated $500M+ in sales in 2021.","Upon closing, Kind will become a wholly owned subsidiary, consolidating its financials with MariMed.","MariMed (OTCQX: MRMD) expects to close the previously announced acquisition following this approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389521,"accession_number":"0001493152-22-007359","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2022-03-21T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MariMed announces Q4/FY2021 earnings; no specific figures disclosed in provided text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Company issued press release on March 16, 2022, announcing financial results for Q4 and full year 2021.","Investor conference call held March 17, 2022 (transcript furnished as Exhibit 99.2).","Neither press release nor transcript excerpt contains reported revenue, EPS, or guidance figures.","Filing does not include any material operational updates or forward-looking statements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389520,"accession_number":"0001493152-22-000383","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2022-01-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"MariMed agrees to acquire Kind Therapeutics USA for $20M; buys minority interests for $2M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquires 100% of Kind Therapeutics for $20M: $13.5M cash, $6.5M in 4-year 6% promissory notes.","Also buys minority interests in two subsidiaries for $2M, gaining ~99.7% of Mari-MD and ~94.3% of Mia.","Kind holds Maryland medical cannabis licenses for cultivation, production, and provisional dispensary.","Closing subject to Maryland Medical Cannabis Commission approval; related litigation dismissed with prejudice.","CEO Bob Fireman expects another transformational year; MariMed already manages Kind's operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407466,"accession_number":"0001493152-21-029225","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2021-11-18T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MariMed reports Q3 2021 results; no specific figures in filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release issued on November 15, 2021 for Q3 2021 financial results.","Investor conference call held on November 16, 2021 to discuss results.","Results cover three and nine months ended September 30, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":90420280.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426472,"accession_number":"0001493152-21-023974","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2021-09-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MariMed shareholders approve charter amendment to increase authorized shares to 700M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five incumbent directors re-elected with >98% of votes cast for each.","Charter amendment to increase authorized common shares from 500M to 700M approved (228.7M for, 22.1M against).","Advisory vote to ratify M&K CPAs as auditors passed with 249.9M votes for.","Amendment to 2018 Stock Award and Incentive Plan approved with 164.7M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426471,"accession_number":"0001493152-21-020701","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2021-08-19T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MariMed Q2 revenue $32.6M (+239% YoY); raises FY2021 guidance to $118M revenue, $32M EBITDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $32.6M, up 239% YoY and 32% QoQ; net income $7.6M vs loss $1.1M in Q2 2020.","EBITDA $12.3M (+440% YoY); Adjusted EBITDA $13.9M (43% margin).","Raises FY2021 guidance: revenue to $118M (from $100M), EBITDA to $32M (from $30M); first-time Adj. EBITDA guide of $42M.","Positive operating cash flow $10.8M; working capital $20.9M, up $7.2M from Q1.","Growth driven by wholesale in MA, retail in MA/IL, and branded product licensing in six states."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":57212220.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426470,"accession_number":"0001493152-21-016534","cik":1522767,"company_name":"MARIMED INC.","ticker":"MRMD","form_type":"8-K","filed_at":"2021-07-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"MariMed signs 3-year employment deals for CEO, CFO, COO with base salaries and option grants","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Robert Fireman, CFO Jon Levine, COO Timothy Shaw each entered new 3-year employment agreements effective July 1, 2021.","CEO base salary $350k, CFO $325k, COO $300k; each eligible for annual bonus target 75% of base salary.","CEO granted options for 5M shares vesting 50% now and 50% in 1 year; additional 5M upon stockholder approval.","COO Timothy Shaw granted options for 1.25M shares on same vesting schedule; CFO Levine terms same as CEO except salary.","Severance on without-cause/good-reason termination: lump sum = greater of $500k or 100% of annualized pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30344223.093333337,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}